Efficacy of Transarterial Embolization with Arsenic Trioxide Oil Emulsion in a Rabbit VX2 Liver Tumor Model

Journal of Vascular and Interventional Radiology

Volumn 20, Issue 10, 2009, Pages 1365-1370

  Kim, Hye Jin ^a   Shin, Ji Hoon ^a   Kim, Tae Hyung ^a   Kim, Eun Young ^a   Park, Young Soo ^a   Park, Chan Sik ^a   Song, Ho Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; IODINATED POPPYSEED OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; EMULSION; HISTOPATHOLOGY; LIVER CARCINOMA; LIVER TOXICITY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ARSENIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EMBOLIZATION, THERAPEUTIC; EMULSIONS; HEMOSTATICS; HUMANS; IODIZED OIL; LIVER; LIVER NEOPLASMS; RABBITS; TREATMENT OUTCOME;

EID: 70349451567     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2009.07.005     Document Type: Article

References (36)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 5 suppl 1 (2004) S35-S50
3. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
5. Bruix J., Sala M., and Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 5 suppl 1 (2004) S179-S188
6. Takayasu K., Arii S., Ikai I., et al. Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131 (2006) 461-469
7. Sasaki Y., Imaoka S., Kasugai H., et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60 (1987) 1194-1203
8. Nakamura H., Hashimoto T., Oi H., et al. Treatment of hepatocellular carcinoma by segmental hepatic artery injection of Adriamycin-in-oil emulsion with overflow to segmental portal veins. Acta Radiol 31 (1990) 347-349
9. Uchida H., Ohishi H., Matsuo N., et al. Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13 (1990) 140-145
10. Wang S.S., Zhang T., Wang X.L., Hong L., and Qi Q.H. Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxicity. World J Gastroenterol 9 (2003) 930-935
11. Siu K.P., Chan J.Y., and Fung K.P. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 71 (2002) 275-285
12. Shen Z.X., Chen G.Q., Ni J.H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
13. Soignet S.L., Maslak P., Wang Z.G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339 (1998) 1341-1348
14. Lazo G., Kantarjian H., Estey E., Thomas D., O'Brien S., and Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 97 (2003) 2218-2224
15. Akao Y., Nakagawa Y., and Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455 (1999) 59-62
16. Seol J.G., Park W.H., Kim E.S., et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 265 (1999) 400-404
17. Zhang T.C., Cao E.H., Li J.F., Ma W., and Qin J.F. Induction of apoptosis and inhibition of human gastric cancer MCG-803 cell growth by arsenic trioxide. Eur J Cancer 35 (1999) 1258-1263
18. Maeda H., Hori S., Nishitoh H., et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61 (2001) 5432-5440
19. Kito M., Akao Y., Ohishi N., Yagi K., and Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 291 (2002) 861-867
20. Nakagawa Y., Akao Y., Morikawa H., et al. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70 (2002) 2253-2262
21. Pu Y.S., Hour T.C., Chen J., Huang C.Y., Guan J.Y., and Lu S.H. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - characterizing its apoptotic pathway. Anticancer Drugs 13 (2002) 293-300
22. Park W.H., Cho Y.H., Jung C.W., et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300 (2003) 230-235
23. Shen Z.Y., Zhang Y., Chen J.Y., et al. Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts. Oncol Rep 11 (2004) 155-159
24. Zhang T., Wang S.S., Hong L., Wang X.L., and Qi Q.H. Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res 22 (2003) 61-68
25. Xu H.Y., Yang Y.L., Liu S.M., Bi L., and Chen S.X. Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World J Gastroenterol 10 (2004) 3677-3679
26. Tan B., Huang J.F., Wei Q., Zhang H., and Ni R.Z. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol 11 (2005) 5938-5943
27. Liu B., Pan S., Dong X., et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 97 (2006) 675-681
28. Huang S.Y., Chang C.S., Tang J.L., et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103 (1998) 1092-1095
29. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington DC 56-70
30. Watanabe D., Ueo H., Inoue H., et al. Antitumor effects of intraarterial infusion of tumor necrosis factor/Lipiodol emulsion on hepatic tumor in rabbits. Oncology 52 (1995) 76-81
31. Okada M., Kudo S., Miyazaki O., et al. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit Vx2 tumour model. Br J Cancer 71 (1995) 518-524
32. Davison K., Mann K.K., and Miller Jr. W.H. Arsenic trioxide: mechanisms of action. Semin Hematol 39 2 suppl 1 (2002) S3-S7
33. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 62 (2002) 3893-3903
34. Kidd J.G., and Rous P. A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form. J Exp Med 71 (1940) 813-838
35. Karasulu H.Y., Karabulut B., Kantarci G., et al. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. Drug Deliv 11 (2004) 345-350
36. Sipahioglu M.H., Saglam E., Oymak O., et al. Effect of cyclosporine A on total homocysteine level in a rabbit model. Transplant Proc 37 (2005) 2371-2374